Opinion|Videos|September 30, 2024
Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
Key Takeaways
- Enhancing physician awareness and understanding of SGLT2 inhibitors and GLP1-receptor agonists can increase prescription rates.
- Streamlining insurance approval processes and advocating for policy changes are crucial for improving medication coverage.
The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.
Episodes in this series
Video content above is prompted by the following:
- Despite being approved for first-line treatment, medications such as SGLT2 inhibitors and GLP1-receptor agonists are not frequently prescribed to qualified patients. What has been effective in your practice to get these first line medications covered in the patient population who needs it the most?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Related to this article
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
Community Oncologists Ready to Innovate, but Barriers Remain
5